Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cardlytics, Inc. (NASDAQ: CDLX) announced that on Aug. 3, 2026, Cardlytics granted an aggregate of 50,000 restricted stock units of Cardlytics to its newly appointed Chief Legal Officer, Chris Cheng. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the “2022 Inducement Plan”).
The restricted stock units shall vest over a period of 24 months, with 25,000 shares vesting on September 1, 2027 and the remaining shares vesting quarterly over the subsequent 12 months, subject to Cheng’s continuous service with Cardlytics through each vesting date. The restricted stock units are subject to the terms and conditions of the 2022 Inducement Plan.
About Cardlytics
Cardlytics (NASDAQ: CDLX) is a purchase intelligence platform that transforms $5.8 trillion in annual transaction data into smarter growth strategies for brands and more rewarding experiences for consumers. With visibility into one of every two card-based transactions in the U.S. and U.K., Cardlytics delivers the scale and depth of purchase intelligence that no other platform can match. Brands activate that intelligence through personalized, card-linked offers that drive measurable results across leading banking and commerce platforms worldwide. Since 2008, Cardlytics has delivered $1.2 billion in rewards to consumers. Learn more at www.cardlytics.com or follow us on LinkedIn.
Investor Relations:
ir@cardlytics.com
Public Relations:
pr@cardlytics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260803128432/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
10 Best Blue-Chip Stocks to Buy for the Long Term
United States